Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 13.50
Ask: 14.50
Change: -0.25 (-1.75%)
Spread: 1.00 (7.407%)
Open: 14.25
High: 14.00
Low: 13.75
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Extension

24 Jan 2006 07:01

Angle PLC24 January 2006 For Immediate Release 24 January 2006 ANGLE plc Contract Extension: Innovation Support Project with the London Development Agency ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology is pleased to announce that it has won acontinuation of the SME Innovation Support Project with the London DevelopmentAgency for a further two years. The project extension has a total contract valueof £2.2 million, of which £800,000 is ANGLE fees with the balance being grantsto companies and project expenditure. The contract extension runs from January2006 for 27 months. The extension of the SME Innovation Support Project, which is part-funded by theEuropean Regional Development Fund, builds on the successful delivery ofconsulting work provided by ANGLE to over 50 SME organisations. The aim is nowto work with over 150 companies to generate over 50 products, stimulatinginnovation within the London Objective area by providing easier access toexpertise, particularly from London's universities and research institutions. The Innovation Support Project also addresses local needs by increasingcompetitiveness of SMEs through improved innovation and technology assistance.Specifically, it aims to: • Raise understanding of innovation and the benefits it can bring to abusiness; • Help SMEs to identify innovation needs and opportunities; • Facilitate links to sources of innovation and knowledge and supportthe transfer and exploitation of knowledge; • Provide small scale grant funding to encourage SMEs to implement andexploit identified knowledge and innovation opportunities; • Encourage collaborative innovation and technology transfer betweenacademic and research institutions and business; • Build on the success of the current project to develop a pan-Londondelivery model. Andrew Newland, Chief Executive of ANGLE plc said: "We are delighted to have been awarded this significant contract extension,which highlights the success that we are presently experiencing in our UKconsulting business and strengthens our platform for ventures activity." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update
3rd Jun 20157:00 amRNSAppointment of Scientific Adviser
26th May 20157:01 amRNSNew Patent Grants
21st Apr 20157:00 amRNSOvarian Cancer Update
20th Apr 20157:00 amRNSSidney Kimmel Cancer Centre
14th Apr 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSOffer to Shareholders
25th Feb 20151:11 pmRNSIssue of Equity
20th Feb 20154:05 pmRNSHolding(s) in Company
16th Feb 20157:01 amRNSMD Anderson Collaboration
16th Feb 20157:00 amRNSPlacing, Subscription and Offer
29th Jan 20157:00 amRNSInterim Results
27th Jan 20157:01 amRNS"Unprecedented Specificity" in Ovarian Cancer
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
21st Jan 20153:00 pmRNSFurther information re Director's share transfer
19th Jan 20157:00 amRNSNotification of Interim Results
8th Jan 20157:00 amRNSCorporate Collaboration
15th Dec 20147:00 amRNSCancer Research Manchester Institute Publication
12th Nov 20147:00 amRNSFurther information re Director's share transfer
10th Nov 20147:00 amRNSIssue of Share Options
31st Oct 20147:00 amRNSADR PROGRAMME
21st Oct 20147:00 amRNSDirector's Share Transfer
17th Oct 20147:00 amRNSCollaboration with Barts Cancer Institute
17th Oct 20147:00 amRNSKey Opinion Leaders Report on Parsortix System
30th Sep 20144:30 pmRNSResult of AGM
30th Sep 20147:00 amRNSCollaboration with Thomas Jefferson University
25th Sep 20147:00 amRNSADR Programme, FDA Update and US Appointment
19th Sep 20147:00 amRNSBreast Cancer Collaboration
17th Sep 20147:00 amRNSCollaboration with Medical University of Vienna
8th Sep 20147:00 amRNSHamburg-Eppendorf Collaboration
4th Aug 20147:00 amRNSParsortix Granted Second US Patent
23rd Jul 20147:00 amRNSPreliminary Results
22nd Jul 20147:00 amRNSParsortix Evaluation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.